Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline in Patients With Nonalcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients ages 18 to 70 years.~* Liver biopsy compatible with NASH, including presence of steatosis and necroinflammatory activity on liver biopsy done during the prior 6 months to study enrollment~* Daily alcohol intake of \<30 g for males and \<15 g for females;~* Appropriate exclusion of other liver diseases.~* Patients with diabetes mellitus type 2 diagnosis as defined by a previous diagnosis of DM and current therapy with antidiabetic agents, or by fulfillment of 1997 American Diabetic Association (ADA) criteria, may be included if they fulfill the following criteria: (i) therapeutic regimen limited to specific oral agents including sulfonylureas (e.g. glipizide and glyburide) and/or biguanides (e.g. metformin); (ii) stable therapeutic regimen as defined by no changes in oral agents for at least 3 months; (iii) Hemoglobin A1C (HgbA1C) \< 8.5 %.~Exclusion Criteria:~* History of past excessive alcohol drinking (as defined above) for a period longer than 2 years at any time in the past 10 years.~* Current consumption of alcohol \>30 g daily for males and \>15 g daily for females.~* Positive testing for hepatitis B surface antigen, hepatitis C virus antibody, or ribonucleic acid (RNA) of hepatitis C virus of deoxyribonucleic acid (DNA) of hepatitis B virus.~* Patients taking medications known to cause steatosis.~* Other causes of liver disease suspected by history, family interview, or laboratory testing.~* Patients with cirrhosis defined by stage 4 fibrosis on liver biopsy, or if the patient shows unequivocal clinical evidence of portal hypertension, such as thrombocytopenia, splenomegaly, or esophageal varices.~* Patients taking medications of possible benefit in NASH within 3 months prior to the liver biopsy. These medications include Vitamin E, Betaine, S-adenosylmethionine (SAM-e), thiazolidinediones, and acarbose.~* Patients with diabetes mellitus who are on Insulin therapy.~* Patients with diabetes mellitus on therapy with thiazolidinediones or alpha-glucosidase inhibitors such as acarbose~* Hypersensitivity to pentoxifylline or the methylxanthines (caffeine, theophylline, theobromine).~* History of cerebral or retinal hemorrhage.~* Other medical comorbidities (such as cardiac, central nervous system, renal, cancer) that would interfere with completion of the study.~* Patients taking Theophylline or Coumadin because of potential drug-drug interactions with Pentoxifylline.~* Pregnant or nursing women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Pentoxifylline (PTX) 400 mg by mouth (PO) three times daily (TID)
- 2 (Type: PLACEBO_COMPARATOR): Placebo three times daily (TID)

Based on this trial design, predict the completion outcome and termination type (if applicable).